RPT193 is an orally-administered small molecule CCR4 antagonist that blocks the recruitment of inflammatory immune cells, known as Th2 cells, which are clinically implicated in a broad range of inflammatory disorders. As there are existing injectable clinical products that are efficacious, as well as emerging oral drug candidates with potential safety liabilities, we believe there remains an unmet need for a safe, highly effective oral treatment.
We have completed a a randomized, placebo-controlled, Phase 1b trial in patients with atopic dermatitis, in which RPT193 demonstrated clinically meaningful improvement in several key exploratory endpoints after 4 weeks of treatment with further improvement for two weeks after completion of treatment. In addition, RPT193 was well-tolerated with only mild or moderate adverse events. These early data may suggest that this novel mechanism of action targeting CCR4 on Th2 cells could have prolonged effects along with good safety and oral convenience, which could differentiate it from the injectables and other oral agents.